Last reviewed · How we verify

Continued cotrimoxazole prophylaxis

Medical Research Council · FDA-approved active Small molecule Quality 5/100

Continued cotrimoxazole prophylaxis is a Small molecule drug developed by Medical Research Council. It is currently FDA-approved. Also known as: trimethoprim+sulfamethoxazole.

At a glance

Generic nameContinued cotrimoxazole prophylaxis
Also known astrimethoprim+sulfamethoxazole
SponsorMedical Research Council
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Continued cotrimoxazole prophylaxis

What is Continued cotrimoxazole prophylaxis?

Continued cotrimoxazole prophylaxis is a Small molecule drug developed by Medical Research Council.

Who makes Continued cotrimoxazole prophylaxis?

Continued cotrimoxazole prophylaxis is developed and marketed by Medical Research Council (see full Medical Research Council pipeline at /company/medical-research-council).

Is Continued cotrimoxazole prophylaxis also known as anything else?

Continued cotrimoxazole prophylaxis is also known as trimethoprim+sulfamethoxazole.

What development phase is Continued cotrimoxazole prophylaxis in?

Continued cotrimoxazole prophylaxis is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing